Clinical trial HER2CLIMB-02
Randomized, double-blind, Phase III Trial of tucatinib or Placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Seagen |
| EudraCT Identifier | 2019-005017-39 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03975647 |
| Last update |